| Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
|
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
|
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
| The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications |
|
Cells |
Myelodysplastic Syndromes (MDS) |
| Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience |
|
Cancers |
Myelodysplastic Syndromes (MDS), Pediatric |
| Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
|
Cancers |
Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS) |
| Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium |
|
Cancer Medicine |
Myelodysplastic Syndromes (MDS) |
| Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. |
|
Cancer Med |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
|
Cancer Management and Research |
Myelodysplastic Syndromes (MDS) |
| Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
| Alcohol use is not a significant contributor to myelodysplastic syndromes |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
